Prices have been disclosed for 32 NME therapeutics approved by FDA in 2012. Eighteen cost more than $30,000 for a course of treatment based on the published wholesale acquisition cost (WAC). The numbers below reflect either a one-year treatment period (for chronic indications) or the median time patients were treated in clinical trials (for acute/cancer indications where treatment is less than one year). Three drugs below must be given as part of combination therapies. Six, all of which have Orphan Drug status, have WACs above $100,000. A full list including 14 additional NME